Valneva SE · EURONEXT:VLA
Valneva — Shareholder Meeting (June 2022)
79 slides from Valneva's shareholder meeting presentation, Jun 23, 2022
Slide 1: 2022 Combined General Meeting
2022 Combined General Meeting Valneva SE June 23, 2022 Paris
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Valneva is a European company. Information d
Slide 3: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 4: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 5: Preliminary formalities
Preliminary formalities Sign attendance sheet (All) Appoint AGM committee (Chair, Observers, Secretary) Validation of the Quorum (Secretary) Documents filed with the AGM committee (Secretary) Agenda (Chairperson) VALNEVA - Combined General Meeting June 23, 2022 5
Slide 6: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 7: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 8: Valneva in Summary
Valneva in Summary Fully integrated specialty vaccine company focused on development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need ◼ Highly specialized and targeted approach to development of unique prophylactic vaccines ◼ Advanced pipelin
Slide 9: Commercial Portfolio
Valneva has an Advanced Clinical Pipeline and Three Approved Products1 Upcoming Development Program Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Milestones Partners Ph3 trial initiation VLA152: expected in Q3 Lyme disease 2022 Clinical Portfolio BLA filing VLA15533: Potentially expected
Slide 10: VLA15: Multivalent Lyme Disease Vaccine Candidate
VLA15: Multivalent Lyme Disease Vaccine Candidate Only Lyme Disease Program in Advanced Clinical Development Today 1 FDA Fast Track Designation granted 2 Exclusive, worldwide partnership with Pfizer Positive results reported from Phase 2 trials1,2,3, incl. first pediatric data 3 and booster response
Slide 11: VLA15: Development Progress and Outlook
VLA15: Development Progress and Outlook Positive Phase 2 Results in Adults1,2,3,4 and Pediatric Participants5 Reported VLA15-221 Phase 2 trial recruited 625 randomized participants, 5 to 65 years of age2 ▪ Strong immunogenicity profile for both adult and pediatric participants reported in February 3
Slide 12: VLA1553: Single Shot Chikungunya Vaccine Candidate
VLA1553: Single Shot Chikungunya Vaccine Candidate Most Clinically Advanced Chikungunya Vaccine Program Worldwide Final positive pivotal Phase 3 results1 and lot-to-lot data2 reported; Adolescent Phase 3 trial 1 initiated in January 20223 FDA Breakthrough Therapy4, Fast Track5 and EMA PRIME7 designa
Slide 13: VLA1553: Development Outlook
VLA1553: Development Outlook Pre-submission Discussions with the US FDA Initiated First and only program to have reported positive Phase 3 results worldwide ▪ Six-month follow-up completed - all Phase 3 immunogenicity and safety endpoints met - seroprotection in 98.9% of participants after one month
Slide 14: VLA2001: Inactivated Whole Virus COVID-19 Vaccine Candidate
VLA2001: Inactivated Whole Virus COVID-19 Vaccine Candidate Only Inactivated COVID-19 Vaccine Program in the Clinic in Europe Builds on Valneva’s IXIARO® manufacturing technology, combined with Dynavax’s CpG 1 1018 adjuvant1 UK MHRA Conditional Marketing Authorization2 and Bahraini NHRA3, United Ara
Slide 15: VLA2001: Pivotal Phase 3 Cov-Compare Study Results
VLA2001: Pivotal Phase 3 “Cov-Compare Study” Results Immunogenicity Safety and Tolerability • VLA2001 met its co-primary endpoints vs • VLA2001 was generally well tolerated: AZD1222, demonstrating: o Significantly more favorable profile compared to o Superiority in terms of geometric mean titer for
Slide 16: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 17: Key milestones met in 2021
Key milestones met in 2021 Lyme disease vaccine candidate VLA15 ✓ Positive Phase 2 results, incl. booster response ✓ Launch of first study including pediatric population Chikungunya vaccine candidate VLA1553 R&D ✓ Positive pivotal Phase 3 and lot-to-lot data ✓ Awarded FDA Breakthrough Designation fo
Slide 18: Valneva continued to deliver in H1 2022
Valneva continued to deliver in H1 2022 Lyme disease vaccine candidate VLA15 ✓ Updated the terms of the collaboration and license agreement with Pfizer; confirmed Phase 3 initiation in the third quarter of 2022 ✓ Reported further positive Phase 2 data, including pediatrics, with Pfizer Chikungunya v
Slide 19: Key Upcoming Catalysts and News Flow in 2022
Key Upcoming Catalysts and News Flow in 2022 Lyme disease vaccine candidate VLA15 ▪ Phase 3 trial initiation expected in Q3 2022 Chikungunya vaccine candidate VLA1553 ▪ Biologics License Application (BLA) filing expected in H2 2022 COVID-19 vaccine candidate VLA2001 ▪ Potential additional regulatory
Slide 20: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 21: Full Year 2021 Financials: Total Revenues of €348m
Full Year 2021 Financials: Total Revenues of €348m Growth attributed to recognized revenues from terminated UK agreement DUKORAL® €2.4m €348.1m IXIARO® Third Party US Military Products1 €38.0m €15.4m Net DUKORAL® product sales €63.0m €2.4m IXIARO®/ JESPECT® €110.3m Travel market €7.1m €63.0m €65.9m
Slide 22: Full Year 2021 Financials: Product Sales of €63m
Full Year 2021 Financials: Product Sales of €63m Continued pandemic impact on travel industry, strong increase in third party product sales €m FY 2021 FY 2020 % (audited) (audited) IXIARO®/JESPECT® 45.1 48.5 -6.9% DUKORAL® 2.4 13.3 -81.7% Third party products 15.4 4.2 +271.0% Total 63.0 65.9 -4.5% V
Slide 23: Full Year 2021 Financials: EBITDA of -€47.1m
Full Year 2021 Financials: EBITDA of - €47.1m Reflects Pandemic Impact on Sales and Significant R&D Investments €m (2020 unaudited) FY 2021 FY 2020 Product sales 63.0 65.9 Other Revenues 285.1 44.4 Revenues 348.1 110.3 Cost of goods and services (187.9) (54.3) Research and development expenses (173.
Slide 24: Full Year 2021 Financials: Balance Sheet 2020/2021
Full Year 2021 Financials: Balance Sheet 2020/2021 Net Assets impacted by COVID-19 as well as cash proceeds from public offerings December 31st, December 31st, €m (2021 audited) 2021 2020 NON-CURRENT ASSETS 231.5 140.7 - Property, Plant & Equipment 125.5 34.8 - Other Non-current Assets 106.0 106.0 C
Slide 25: Full Year 2021 Financials: Balance Sheet 2020/2021 (cont.)
Full Year 2021 Financials: Balance Sheet 2020/2021 (cont.) Liabilities & Equity increased due to COVID-19 contracts and public offerings December 31st, December 31st, €m (2021 audited) 2021 2020 EQUITY 170.6 77.4 NON-CURRENT LIABILITIES 277.8 195.9 - Refund Liabilities 159.0 97.2 - Other Non-Current
Slide 26: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 27: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 28: 2021 Consolidated financial statements: Statutory Auditors' report
2021 Consolidated financial statements Excerpts from the Statutory Auditors’ report “In our opinion, the consolidated financial statements give a true and fair view of the assets and liabilities and of the financial position of the Group as at December 31, 2021 and of the results of its operations f
Slide 29: 2021 Parent entity financial statements: Statutory Auditors' report
2021 Parent entity financial statements Excerpts from the Statutory Auditors’ report “In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the Company as at 31 December 2021 and of the results of its operations for the year
Slide 30: Related-party agreements
Related-party agreements Excerpts from the Statutory Auditors’ special report + Agreements authorized and executed during the fiscal year 2021 ▪ Directors and officers indemnification agreements ✓ The agreements, authorized by the supervisory board on May 5, 2021, undertake the Company - to the full
Slide 31: Related-party agreements
Related-party agreements Excerpts from the Statutory Auditors’ special report + Agreements authorized and executed during the fiscal year 2021 ▪ Amendments 3, 4 and 5 to the Collaboration and Research Licence Agreement and Amendment 3 to the Premises and Equipment Provision Agreement, concluded with
Slide 32: Related-party agreements
Related-party agreements Excerpts from the Statutory Auditors’ special report + Agreements authorized and executed during the fiscal year 2021 ▪ Amendment 1 to the 2019-2022 Management Agreement executed between Mr. Franck Grimaud and Valneva on March 4, 2021 ✓ Amendment 1 to the 2019-2022 Managemen
Slide 33: Related-party agreements
Related-party agreements Excerpts from the Statutory Auditors’ special report + Agreements authorized and executed during the fiscal year 2021 ▪ Amendment 1 to the 2019-2022 Management Agreement executed between Mr. Frédéric Jacotot and Valneva on March 4, 2021 ✓ Amendment 1 to the 2019-2022 Managem
Slide 34: Related-party agreements
Related-party agreements Excerpt from the Statutory Auditors’ report + Agreements already approved by the Annual General Meeting and in place during the fiscal year 2021 ▪ Collaboration and Research License Agreement & Premises and Equipment Provision Agreement and related Amendments 1 et 2 to the C
Slide 35: Related-party agreements
Related-party agreements Excerpt from the Statutory Auditors’ report + Agreements already approved by the Annual General Meeting and in place during the fiscal year 2021 ▪ Management Agreement with Mr. Franck Grimaud and Valneva executed on July 9, 2018 ✓ The Management Agreement 2019-2022 authorize
Slide 36: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 37: Important note on resolutions
IMPORTANT NOTE Some of the resolutions shown on the following slides have been summarized. For the full text version, please refer to the “Investors” / “General Meetings” / “2022 Combined General Meeting” section of Valneva’s website www.valneva.com. The English resolutions and their English summari
Slide 38: Resolution 1 - Approval of parent-entity financial statements
Resolution 1 - Approval of the parent-entity financial statements for the fiscal year ended December 31, 2021 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after having reviewed the parent-entity financial statements
Slide 39: Resolution 2 - Approval of consolidated financial statements
Resolution 2 - Approval of the consolidated financial statements for the fiscal year ended December 31, 2021 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after having reviewed the consolidated financial statements an
Slide 40: Resolution 3 - Appropriation of earnings
Resolution 3 - Appropriation of earnings for the fiscal year ended December 31, 2021 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, resolve to allocate to retained earnings (accumulated deficit) the total loss of twent
Slide 41: Resolution 4 - Approval of regulated agreements
Resolution 4 - Approval of regulated agreements governed by Articles L. 225-86 et seq. of the French Commercial Code The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after having reviewed the Statutory Auditors’ Special Report
Slide 42: Resolution 5 - Reappointment of Supervisory Board Member
Resolution 5 - Reappointment of a Supervisory Board Member (Mr. Frédéric Grimaud) The Shareholders, acting in accordance with the quorum and majority requirements appliable to Ordinary General Meetings, reappoint Mr. Frédéric Grimaud as a member of the Supervisory Board for a three-year (3) term exp
Slide 43: Resolution 6 - Reappointment of Supervisory Board Member
Resolution 6 - Reappointment of a Supervisory Board Member (Mr. James Sulat) The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, reappoint Mr. James Sulat as member of the Supervisory Board for a three-year (3) term expirin
Slide 44: Resolution 7 - Reappointment of Supervisory Board Member
Resolution 7 - Reappointment of a Supervisory Board Member (Ms. Anne-Marie Salaün) The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, reappoint Ms. Anne-Marie Salaün (name used: Graffin) as member of the Supervisory Board
Slide 45: Resolution 8 - Appointment of Bpifrance Participations
Resolution 8 - Appointment of a new Supervisory Board Member (Bpifrance Participations) The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, appoint the company Bpifrance Participations, registered with the Trade and Compani
Slide 46: Resolution 9 - Appointment of Supervisory Board Member
Resolution 9 - Appointment of a new Supervisory Board Member (Mr. James Edward Connolly) The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, appoint Mr. James Edward Connolly as member of the Supervisory Board, for a three-
Slide 47: Resolution 10 - Supervisory Board compensation
Resolution 10 - Setting the compensation allocated to Supervisory Board members The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, set the total amount of the compensation to be divided between Supervisory Board members as
Slide 48: Resolution 11 - Compensation policy, Management Board
Resolution 11 - Approval of the compensation policy applicable to the Management Board members The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by the Supervisory Board on the Corporate Gover
Slide 49: Resolution 12 - Compensation policy, Supervisory Board
Resolution 12 - Approval of the compensation policy applicable to the Supervisory Board members The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by the Supervisory Board on the Corporate Gove
Slide 50: Resolution 13 - Information under Article L. 22-10-9
Resolution 13 - Approval of the information referred to in Article L. 22-10-9, I of the French Commercial Code, pursuant to Article L. 22-10-34, I of the French Commercial Code The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meet
Slide 51: Resolution 14 - Compensation of Chair of Management Board
Resolution 14 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2021, to Mr. Thomas Lingelbach, Chair of the Management Board The Shareholders, acting in acco
Slide 52: Resolution 15 - Compensation of Management Board members
Resolution 15 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2021, to the Management Board members (other than the Chair of the Management Board) The Share
Slide 53: Resolution 16 - Compensation of Chair of Supervisory Board
Resolution 16 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2021, to Mr. Frédéric Grimaud, Chair of the Supervisory Board The Shareholders, acting in acco
Slide 54: Resolution 17 - Share buyback authorization
Summary of Resolution 17 - Authorization and powers to be given to the Management Board for the purpose of allowing the Company to make transactions on its own shares Authorization to the Company, for a period of 18 months as from this Meeting, in order to: › purchase its own shares up to a maximum
Slide 55: Resolution 18 - Amendments to Articles of Association (1/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (1/6) The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after considering the Management Board Report, decide to modify the Company's Art
Slide 56: Resolution 18 - Amendments to Articles of Association (2/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (2/6) VALNEVA - Combined General Meeting June 23, 2022 56
Slide 57: Resolution 18 - Amendments to Articles of Association (3/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (3/6) VALNEVA - Combined General Meeting June 23, 2022 57
Slide 58: Resolution 18 - Amendments to Articles of Association (4/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (4/6) VALNEVA - Combined General Meeting June 23, 2022 58
Slide 59: Resolution 18 - Amendments to Articles of Association (5/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (5/6) VALNEVA - Combined General Meeting June 23, 2022 59
Slide 60: Resolution 18 - Amendments to Articles of Association (6/6)
Resolution 18 - Amendments and harmonization of the Company’s Articles of Association (6/6) VALNEVA - Combined General Meeting June 23, 2022 60
Slide 61: Resolution 19 - Cancellation of treasury shares
Resolution 19 - Authorization granted to the Management Board to cancel treasury shares The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after having reviewed the Management Board Report and the Statutory Auditors’ Report,
Slide 62: Resolution 20 - Capital increase with preferential subscription rights
Summary of Resolution 20 - Grant of authority to the Management Board to increase the share capital by issuing ordinary shares or any securities giving access to the capital while maintaining the preferential subscription right of the shareholders › Delegation for a maximum period of twenty-six (26)
Slide 63: Resolution 21 - Capital increase through public offering
Summary of resolution 21 - Grant of authority to the Management Board to increase the capital by issuing ordinary shares or any securities giving access to the capital through a public offering (other than those referred to in Article L.411-2, 1° of the French Monetary and Financial Code), canceling
Slide 64: Resolution 22 - Capital increase through private placement
Summary of resolution 22 - Grant of authority to the Management Board to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company's share capital, with cancellation of preferential subscription rights of the shareholders, through a public of
Slide 65: Resolution 23 - Setting issue price
Summary of resolution 23 - Grant of authority to the Management Board in the event of an issue of the Company’s ordinary shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, to set th
Slide 66: Resolution 24 - Capital increase for certain categories of persons
Summary of resolution 24 - Grant of authority to the Management Board to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders for the benefit of c
Slide 67: Resolution 25 - Increase in number of shares issued
Resolution 25 - Grant of authority to the Management Board to increase the number of shares to be issued in the case of a capital increase, with or without preferential subscription rights for existing shareholders, within the limit of 15% of the initial issue amount The Shareholders, in accordance
Slide 68: Resolution 26 - Capitalization of reserves
Resolution 26 - Grant of authority to the Management Board in order to increase the share capital through the capitalization of reserves, earnings or premium The Shareholders, in accordance with the conditions of quorum and majority that apply at Ordinary General Meetings, after having reviewed the
Slide 69: Resolution 27 - Issuance for contributions in kind
Summary of resolution 27 - Grant of authority to the Management Board to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, in consideration fo
Slide 70: Resolution 28 - Maximum aggregate amount of capital increases
Resolution 28 - Maximum aggregate amount of capital increases The Shareholders, in accordance with the conditions of quorum and majority that apply at Extraordinary General Meetings, after having reviewed the Management Board Report and the Statutory Auditors' Special Report: › resolve that the maxi
Slide 71: Resolution 29 - Stock options
Resolution 29 - Grant of authority to the Management Board for the purpose of granting stock options, through one or more issues, for the benefit of employees and/or corporate officers of the Company and its affiliates, entailing waiver by shareholders of their preferential subscription right The Sh
Slide 72: Resolution 30 - Capital increase reserved for employees
Summary of resolution 30 - Grant of authority to the Management Board for the purpose of deciding to carry out a capital increase reserved for employees The Shareholders resolve in accordance with the provisions of article L. 225-129-6 of the French Commercial Code to reserve for the benefit of empl
Slide 73: Resolution 31 - Amendments to Article 13.3
Resolution 31 - Amendments to Article 13.3 of the Company’s Articles of Association The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after considering the Management Board Report, resolves, subject to the condition of appr
Slide 74: Resolution 32 - Share capital reduction via preferred share repurchase
Resolution 32 - Share capital reduction, not due to losses, by an amount of 3,077.10 euros, by means of the repurchase, by the Company, of preferred shares convertible into ordinary shares for the purpose of their cancellation The Shareholders, acting in accordance with the quorum and majority requi
Slide 75: Resolution 33 - Powers for formalities
Resolution 33 - Powers for formalities The Shareholders grant all powers to the holder of an original copy, an excerpt or a copy of these minutes certified as authentic to carry out all necessary processes, filings and formalities or as required by operation of law. VALNEVA - Combined General Meetin
Slide 76: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 77: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 78: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. 2021 business highlights & recent newsflow 6. Valneva 2021 financials 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conc
Slide 79: Valneva
‘WaAvalneva